Research programme: influenza virus haemagglutinin glycoprotein inhibitors- PeptiDream/The Tokyo Metropolitan Institute of Medical Science

Drug Profile

Research programme: influenza virus haemagglutinin glycoprotein inhibitors- PeptiDream/The Tokyo Metropolitan Institute of Medical Science

Alternative Names: Hemagglutinin protein inhibitors - PeptiDream/The Tokyo Metropolitan Institute of Medical Science; iHA 24

Latest Information Update: 11 Apr 2014

Price : $50

At a glance

  • Originator PeptiDream
  • Developer PeptiDream; The Tokyo Metropolitan Institute of Medical Science
  • Class Macrocyclic compounds; Peptides
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Influenza virus infections

Most Recent Events

  • 11 Apr 2014 PeptiDream and The Tokyo Metropolitan Institute of Medical Science collaborate to develop influenza virus haemagglutinin glycoprotein inhibitors for treatment of Influenza virus infections
  • 08 Apr 2014 Preclinical trials in Influenza-A virus H5N1 subtype in Japan (unspecified route)
  • 08 Apr 2014 Preclinical trials in Influenza-A virus H1N1 subtype in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top